Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026
Neuronetics (NASDAQ: STIM) announced management will participate in B. Riley Securities' Mind, Muscle & Vision Summit, an invitation-only institutional investor event at the InterContinental Boston.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Neuronetics (NASDAQ: STIM) announced management will participate in B. Riley Securities' Mind, Muscle & Vision Summit, an invitation-only institutional investor event at the InterContinental Boston.
On July 16, 2026, Neuronetics will join Compass Pathways in a panel on commercializing novel neuropsychiatric drugs and hold one-on-one investor meetings. No webcast is planned.
Details
Market move: STIM +10.64% in the Jul 6 session. B. Riley investor conference appearance
On Jul 6, the day this news came out, STIM closed 10.64% above the previous close. Argus tracked a peak move of +9.5% during that session. Our momentum scanner recorded 20 alerts for this stock that day.
Data tracked by StockTitan Argus for the Jul 6 session.
Key Figures
- Summit date
- July 16, 2026
- B. Riley Securities' Mind, Muscle & Vision Summit panel
- Publication date
- July 06, 2026
- Press release announcement of conference participation
Historical Context
-
Named a new Senior Vice President Sales with RSU inducement grant.
-
Highlighted new real‑world NeuroStar TMS data at CTMSS 2026 meeting.
-
Announced collaboration to add neuronavigation to NeuroStar TMS platform.
-
Reported Q1 2026 revenue growth and reiterated full‑year guidance ranges.
-
Disclosed inducement RSU grants to new non‑executive employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
tms medical
neuropsychiatric medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that management will participate at the B. Riley Securities' Mind, Muscle & Vision Summit, an invitation-only institutional investor event being held in-person at the InterContinental Boston.
Neuronetics will participate in a panel discussion titled "Commercializing the Next Wave of Novel Neuropsychiatric Drugs," alongside Compass Pathways, scheduled for Thursday, July 16, 2026. Management will also be available for one-on-one meetings with institutional investors throughout the day.
This is an in-person, invitation-only event, and there will be no live webcast of the panel discussion.
About Neuronetics
Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar® Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (TMS) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
References
1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.